- Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have completed a submission to the European Medicines Agency (EMA) for a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for 12 years and older.
- Except for the addition to the mRNA of the Omicron BA.4/BA.5 spike protein sequence, all other vaccine components remain unchanged.
- Related: Boosters Are Coming For Dangerous Omicron COVID-19 Variant. Here’s Who May Be Rolling Them Out.
- Preclinical data showed that a booster dose of omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against omicron subvariants.
- Related: Pfizer/BioNTech’s COVID-19 Vaccine Updated Data Shows Around 76% Efficacy In Toddlers.
- The companies have also provided safety data from clinical trials evaluating multiple variant-adapted vaccine candidates based on previous variants of concern.
- Pfizer and BioNTech also applied with the EMA for the Omicron BA.1-adapted bivalent COVID-19 vaccine in July, which is currently under review by the Agency. The Omicron BA.1-adapted and Omicron BA.4/BA.5-adapted bivalent boosters will be available to ship shortly after respective regulatory authorizations and be available for use as early as September.
- Price Action: PFE shares are down 1.39% at $47.24, and BNTX stock is down 2.05% at $145.52 on the last check Friday.
- Photo via Wikimedia Commons
Fear & Greed Index Inches Northwards Amid Sharp Rise In US Stocks
The CNN Money Fear and Greed index is slowly inching toward the "greed" zone, but still remained in the "neutral" zone on Monday following a sharp rise in the US stocks on Friday.
